A GIP medication is a drug that activates receptors for glucose-dependent insulinotropic polypeptide, a gut hormone your body naturally releases after eating. The most well-known GIP medication is tirzepatide, sold as Mounjaro for type 2 diabetes and Zepbound for weight management. These drugs don’t target GIP alone. They activate both GIP and GLP-1 receptors simultaneously, which is why they’re called “dual agonists.” This combination has proven more effective at lowering blood sugar and body weight than older drugs that target GLP-1 alone.
What GIP Does in Your Body
GIP is one of two major “incretin” hormones, the other being GLP-1. When you eat, your gut releases both hormones to help manage the surge of nutrients entering your bloodstream. GIP is actually the more powerful of the two in healthy people: it’s responsible for an estimated 60% to 80% of the insulin your body releases after a meal. Its primary job is signaling your pancreas to produce insulin so your cells can absorb glucose from your blood.
Beyond insulin, GIP plays a direct role in how your body stores fat. It stimulates fat cells to take in and store energy, a process that was essential when food was scarce but now contributes to weight gain and metabolic disease in an era of caloric abundance. GIP also has a unique safety feature: during low blood sugar, it promotes the release of glucagon, a hormone that raises blood sugar back to normal levels. This means GIP-based medications carry a lower risk of dangerously low blood sugar compared to some older diabetes treatments.
Here’s the catch. In people with type 2 diabetes, the body’s response to GIP is largely blunted. The hormone is still released after meals, but the pancreas doesn’t react to it the way it should. This is one reason researchers initially focused on GLP-1 drugs instead. The discovery that pharmacological doses of GIP, especially when combined with GLP-1, could overcome this resistance was a turning point in metabolic medicine.
How GIP Medications Differ From GLP-1 Drugs
GLP-1 drugs like semaglutide (Ozempic, Wegovy) target a single hormone pathway. GIP medications like tirzepatide hit two pathways at once, and the two hormones complement each other in ways that amplify the overall effect.
- Insulin release: Both GIP and GLP-1 stimulate insulin secretion, but through slightly different mechanisms. Activating both receptors produces a stronger insulin response than either one alone.
- Glucagon regulation: GLP-1 suppresses glucagon when blood sugar is high, helping bring levels down. GIP does the opposite during low blood sugar, promoting glucagon release to prevent dangerous drops. Together, they create a more balanced system.
- Fat metabolism: GIP directly encourages fat cells to store energy efficiently and produce adiponectin, a protein linked to better metabolic health. GLP-1 works indirectly through the nervous system to promote fat breakdown. The combination helps reduce harmful fat deposits around organs while maintaining healthier fat tissue overall.
- Appetite: Both hormones act on the brain to reduce hunger, but they appear to do so through overlapping yet distinct pathways, which may explain the greater weight loss seen with dual agonists.
Blood Sugar and Weight Loss Results
The clinical data for tirzepatide has been striking. In a head-to-head trial comparing it against semaglutide (the active ingredient in Ozempic) for type 2 diabetes, tirzepatide lowered HbA1c, the standard measure of long-term blood sugar control, by 2.01% at the lowest dose and 2.30% at the highest. Semaglutide at its standard dose achieved a 1.86% reduction. That gap may sound small, but in diabetes management, even a fraction of a percentage point translates to meaningful reductions in complications over time.
For weight loss, the results have been even more notable. In the SURMOUNT-1 trial, people without diabetes who took the highest dose of tirzepatide lost an average of 20.9% of their body weight over 72 weeks. For someone weighing 250 pounds, that’s roughly 52 pounds. This level of weight loss was previously only achievable through bariatric surgery.
What Taking a GIP Medication Looks Like
Tirzepatide is a once-weekly injection given under the skin, typically in the abdomen, thigh, or upper arm. Treatment starts at a low dose of 2.5 mg per week for the first four weeks. This introductory dose isn’t meant to control blood sugar or drive weight loss on its own. It’s designed to let your body adjust and minimize side effects.
After four weeks, the dose increases to 5 mg weekly. From there, your prescriber can bump it up in 2.5 mg increments every four weeks or longer, depending on how you respond and what you can tolerate. The maximum dose is 15 mg per week. Most people spend several months working up to their maintenance dose, so results are gradual rather than immediate.
Common Side Effects
Gastrointestinal symptoms are by far the most frequent issue. Nausea, vomiting, diarrhea, and constipation affect a significant portion of people, particularly during dose increases. These side effects tend to ease over time as your body adjusts, which is part of why the dose is raised slowly.
Less common but more serious concerns include pancreatitis (inflammation of the pancreas causing severe abdominal pain), gastroparesis (where the stomach empties much more slowly than normal), bowel obstruction, and gallstone attacks. The risk of gallstones appears to increase with rapid weight loss generally, not just with these medications specifically. Some people also notice cosmetic changes like facial thinning, sometimes called “Ozempic face,” which results from losing fat in the face alongside overall body fat.
Cardiovascular Effects
GLP-1 receptor agonists have been shown to reduce the risk of major cardiovascular events, including heart attack, stroke, and cardiovascular death, in people with type 2 diabetes. A meta-analysis found a 14% reduction in major adverse cardiovascular events and a 17% reduction in death from any cause among people with diabetes and peripheral artery disease. Dedicated cardiovascular outcomes data specifically for dual GIP/GLP-1 agonists is still being collected, but the GLP-1 component of these drugs is expected to carry similar protective benefits.
What’s Next for GIP-Based Treatments
The next generation of medications in this class targets three hormone receptors instead of two. Retatrutide, currently in phase 3 trials, activates GIP, GLP-1, and glucagon receptors simultaneously. Early phase 2 results showed even greater weight loss than tirzepatide, raising the possibility that triple agonists could push nonsurgical weight loss outcomes further. These drugs are not yet approved, but their development signals that GIP activation will remain central to the next wave of metabolic treatments.